Arcadia Biosciences Announces Closing of $14.0 Million Registered Direct Offering
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
The net proceeds of the offering are estimated to be approximately
The shares of common stock (but not the warrants or the shares of common
stock underlying the warrants) were offered by Arcadia pursuant to a
“shelf” registration statement on Form S-3 that was filed and declared
effective by the
Copies of the final prospectus supplement and accompanying base
prospectus may be obtained on the
The warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are subject to risks and uncertainties that
could cause actual results to differ materially, and reported results
should not be considered as an indication of future performance. These
risks and uncertainties include, but are not limited to: the anticipated
use of proceeds from the offering, the company’s and its partners’ and
affiliates’ ability to identify and isolate desired traits; the demand
for the company’s products, both from commercial partners and consumers;
the company’s and its partners’ ability to develop commercial products
incorporating its traits and complete the regulatory review process for
such products; the company’s compliance with laws and regulations that
impact the company’s business, and changes to such laws and regulations;
the company’s future capital requirements and ability to satisfy its
capital needs; and the other risks set forth in the company’s filings
Arcadia Biosciences, Inc.